Drugs / Remestemcel-L-rknd
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07568535 | Aug 2026 → Feb 2028 expected | acute graft versus host disease | Mesoblast, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-08 | Mesoblast, Inc. | Regulatory Mesoblast R&D Day Features Commercial & Blockbuster Programs mesoblast.com ↗
FDA cleared IND to directly proceed to registrational trial for approval of Ryoncil® in children with Duchenne muscular dystrophy (DMD) |
| 2026-02-12 | Mesoblast, Inc. | Results High Survival Rates with Ryoncil in SR-aGvHD EIND Program mesoblast.com ↗
The study results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease (SR-aGvHD) irrespective whether used in children or adults, as second or third line, and in ruxolitinib naive or resistant patients .1 |
| 2026-01-27 | Mesoblast, Inc. | Results Real World Experience with Ryoncil Shows 84% Early Survival mesoblast.com ↗
Of the first 25 patients treated with Ryoncil® in a ‘real-world’ clinical setting post launch, 21 were alive (84%) and completed the initial 28-day treatment regimen as per the FDA approval label . |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-08 | Mesoblast, Inc. | Mesoblast R&D Day Features Commercial & Blockbuster Programs mesoblast.com ↗ |
| 2026-02-12 | Mesoblast, Inc. | High Survival Rates with Ryoncil in SR-aGvHD EIND Program mesoblast.com ↗ |
| 2026-01-27 | Mesoblast, Inc. | Real World Experience with Ryoncil Shows 84% Early Survival mesoblast.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remestemcel-L-rknd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07568535 ↗ |
| Known as | remestemcel-L | “This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo...” NCT07568535 ↗ |
| Modality | Cell therapy | “Remestemcel-L is comprised of ex-vivo cultured adult human MSC” NCT07568535 ↗ |
| Route | Intravenous | “Remestemcel-L will be administered as intravenous infusions” NCT07568535 ↗ |